KC Urology Care is First Private Practice to Offer PROVENGE® Infusion Site in KC Metro Area

January 1, 2012 — Kansas City, MO — Kansas City Urology Care, PA is proud to now offer prostate cancer patients one of the latest advances in treatment options, the first-in-class immunotherapy, PROVENGE® (sipuleucel-T). KCUC is the first private practice within a 150 mile radius that has been granted a PROVENGE infusion site.

PROVENGE is the only FDA-approved treatment for certain men with advanced prostate cancer that uses the patient’s own immune system to fight the disease. PROVENGE is designed to stimulate a patient’s immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his own immune cells.

"There is a lot of pride in the quality here. We want to deliver world-class service in a private-practice city for KC Urology Care patients," Doctor David F. Emmott M.D.

PROVENGE is not a chemotherapy drug and is different from hormone therapy which decreases the level of testosterone in the body. PROVENGE is an immunotherapy that works by stimulating the natural ability of immune cells already in the patient’s body and may help patients live longer. A typical PROVENGE course of treatment can be completed in about a month, and the most common side effects are primarily mild or moderate.

KCUC First With REZUM®

View Rezūm Patient Education from REZUM on Vimeo.

Kansas City Urology Care is the first practice in Kansas City to offer NxThera’s REZUM® treatment for BPH. REZUM uses radio-frequency (RF) energy to create sterile water vapor to delivery targeted, precise thermal energy treatments in a simple, office-based setting with minimal discomfort. REZUM was FDA cleared in August of 2015.

Schedule an appointment today and ask a KCUC urologist about this therapy.

American College of Radiology Radiation Oncology Accredited Facility
Accredited by the premier credentialing body for radiation oncology, ACR (The American College of Radiology).